VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2021 | Microvascular complications of CGRP antagonists for migraine patients with Raynaud’s phenomenon

Ilana Breen, BS, Mayo Clinic School of Medicine, Scottsdale, AZ, shares the findings of a retrospective cohort study assessing the safety of calcitonin gene-related peptide (CGRP) antagonists for migraine treatment in patients with Raynaud Phenomenon. CGRP antagonists are known to decrease vasodilatory responses, warranting analyses of the microvascular risk profile of these medications in potentially susceptible patients. 169 patients with Raynaud’s phenomenon undergoing CGRP antagonist therapy to treat migraine were included in the study, of whom 5.3% showed microvascular complications including worsening Raynaud phenomenon, digital ulceration, and necrosis requiring amputation. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.